Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Approaches to the Treatment of Hypothyroidism
NCT06731764Phase 3Recruiting
- Sponsor
- UConn Health
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liothyronine in hypothyroidism (3 arms), sponsored by UConn Health. Primary endpoints: Changes in Total Cholesterol at 6 months and Changes in LDL Cholesterol at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
liothyronine
03
Conditions
hypothyroidism
Beyond the preview
Go deeper on NCT06731764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731764.